Galmed Pharmaceuticals Ltd. develops Aramchol, an SCD1 inhibitor drug candidate, as a clinical-stage biopharmaceutical company focused on liver disease, cardiometabolic disease and gastrointestinal oncology therapeutics. Company updates frequently cover Aramchol development in NASH/MASH and fibrosis, combination approaches, patent activity, scientific presentations and efforts to expand the pipeline into oncology and cardiometabolic indications.
Recent developments also include collaborations and formulation work tied to Aramchol-based research, including human organoid models for cardiac fibrosis, preclinical evaluation in metastatic brain cancers and brain-penetrating delivery approaches for CNS-related applications. Other recurring corporate news includes annual-report filings, shareholder communications and Nasdaq listing compliance matters.
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) provided updates on its clinical programs and reported financial results for Q2 2020. The Data Monitoring Committee approved the continuation of the ARMOR Phase 3 trial for NASH without protocol changes, with recruitment resuming earlier than expected. Cash reserves stood at $63.5 million, down from $75.6 million at year-end 2019. The net loss for Q2 was $5.5 million ($0.26 per share), up from $4.2 million the previous year. R&D expenses increased to $5.0 million, reflecting more costs for the manufacturing of Aramchol API. Galmed plans a Phase 1 study for Amilo-5MER.
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) announced updates on its pipeline program, focusing on the development of Amilo-5MER, a synthetic peptide targeting chronic inflammatory diseases. The collaboration with the Hebrew University of Jerusalem highlights significant progress, supported by pre-clinical data indicating efficacy in reducing chronic inflammation. Amilo-5MER, which binds to pro-inflammatory proteins, shows potential for treating conditions like rheumatoid arthritis and COVID-19. The company plans to submit an IND in Q4 2020 and initiate Phase 1 studies, expecting to advance quickly in clinical development.
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) announced a conference call on August 6, 2020, to discuss its financial results for the second quarter of 2020 and updates on its clinical programs for Aramchol, a treatment for nonalcoholic steatohepatitis (NASH) currently in Phase 3 trials. Aramchol has received Fast Track designation from the FDA and aims to address the rising NASH crisis affecting significant populations globally. The call will cover both financial metrics and clinical developments as the company progresses in its research efforts.